Lupin Partners With SteinCares To Supply Biosimilar in LATAM
27 May 2025
1 Min Read
CW Team
Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin鈥檚 biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.
As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.
Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).
Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, 鈥淭his partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients鈥� quality of life.鈥�
Sebasti谩n Katz, Chief Strategy Officer at SteinCares, added, 鈥淥ur collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.鈥�
This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies鈥� missions to deliver impactful healthcare solutions.
Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin鈥檚 biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, 鈥淭his partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients鈥� quality of life.鈥漇ebasti谩n Katz, Chief Strategy Officer at SteinCares, added, 鈥淥ur collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.鈥漈his partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies鈥� missions to deliver impactful healthcare solutions.
Next Story
Ashwin Sheth Group Buys 50% Stake in One Marina
Mumbai-based real estate developer Ashwin Sheth Group has acquired a 50 per cent stake in the Rs 23 billion (USD 275 million) luxury residential project One Marina, located in South Mumbai鈥檚 upscale Marine Lines. The acquisition was announced on 11 June and marks a major move in the city's premium housing market.The stake was acquired from Vallabh Sheth and Jitendra Sheth, promoters of Sheth Creators, who previously co-owned the project along with YM Infra, the landowner. This acquisition was supported by a substantial USD 65 million (over Rs 5.4 billion) investment commitment from PAG Singa..
Next Story
96km Rail Line to Link Rajasthan's Sirohi to Network
In a major step towards improving infrastructure in Rajasthan, the central government has approved the final location survey for a 96-kilometre railway line connecting Marwar Bagra (Jalore)鈥揝irohi鈥揝warupganj, thereby integrating Sirohi district into the national railway network for the first time.The approval, announced on Monday, marks a long-awaited development for tribal-dominated western Rajasthan. Sirohi, currently without a rail link, lies near the important Delhi鈥揂jmer鈥揂bu Road鈥揂hmedabad corridor, while Jalore is already on the Samdari鈥揃hildi鈥揋andhidham route.Railway Minis..
Next Story
Push Grows for Berhampur-Sambalpur Rail Via Phulbani
A coalition of social organisations under the Milita Kriya Anusthan Committee has stepped up its campaign for the construction of a Berhampur鈥揝ambalpur (Rairkhol) railway line via Bhanjanagar and Phulbani, aiming to improve rail connectivity in southern Odisha.On Friday, the group launched a public awareness drive across Ganjam and Kandhamal districts, highlighting the urgent need for the proposed railway route. A "Vikash Rath" bus, carrying around 40 committee members, began its journey from the local railway station, stopping for public meetings in Hinjili, Aska, and Bhanjanagar, with a fo..
